Registry Study for Optimal Management of Liver Failure in the Chinese Population
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: ALF, SALF, ACLF.
- Who it may be relevant to
- Registry conditions: Liver Failure. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Registry Study for Optimal Management of Liver Failure in the Chinese Population (RESOLVE-C)
Overview
Liver failure is the most severe form of liver damage caused by viral, alcoholic, drug-related and ischemia-reperfusion factors, often combined with extrahepatic organ damage, resulting in a high mortality rate. This study intends to construct a real-world case registry database of inpatients with liver failure based on an electronic clinical data collection system through a multicenter collaborative network to study the clinical characteristics, epidemiology of bacterial and fungal infections, the impact of sarcopenia on clinical prognosis, and optimization of treatment strategies such as antiviral and artificial liver in Chinese inpatients with liver failure. The cohort and experience generated from this study will be used as a support for a series of future studies to focus on clinical issues such as infection, end-stage liver disease combined with organ failure, and early warning of critically ill patients.
Interventions
- Procedure ALF
Acute onset, no history of underlying liver disease, liver failure characterized by degree Ⅱ or above hepatic encephalopathy developed within 2 weeks - Procedure SALF
The onset was acute, with no history of underlying liver disease, and clinical manifestations of liver failure appeared between 2 and 26 weeks - Procedure ACLF
On the basis of chronic liver disease, the clinical manifestations of acute liver decompensation and liver failure appear in a short period
Primary outcome measures
- Overall survival [Time frame: 28-day]
- Overall survival [Time frame: 90-day]
Secondary outcome measures (1)
- Disease progression [Time frame: 48 weeks after discharge]
Eligibility criteria
Inclusion criteria
Patients with a diagnosis consistent with liver failure and pre-liver failure:
- Extreme weakness with significant gastrointestinal symptoms such as anorexia, vomiting and abdominal distention;
- Elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) with progressive jaundice (TBil≥85.5 μmol/L);
- Bleeding tendency with PTA ≤ 60% or INR ≥ 1.5.
Exclusion criteria
- An event or complication that, in the judgment of the investigator, significantly affects the assessment of clinical status.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 14 centers
- First Affiliated Hospital of Xi'an Jiaotong University — Xi'an
- Ankang Central Hospital — Ankang
- Xiangya Hospital of Central South University — Changsha
- Hanzhong 3201 Hospital — Hanzhong
- Qilu Hospital of Shandong University — Jinan
- First Hospital of Lanzhou University — Lanzhou
- Weinan Central Hospital — Weinan
- Air Force Medical University Tangdu Hospital — Xi'an
- … and 6 more centers
Publications
- Liu Y, Zhang Q, Li J, Wu X, Zang Q, Wang Q, Huang P, Wang Y, Zhang S, Liu S, Zhu C, Zhao Y, Yan T, He Y. mNGS improves the efficiency of infection diagnosis and treatment in acute-on-chronic liver failure. BMC Gastroenterol. 2026 Jan 20;26(1):129. doi: 10.1186/s12876-025-04601-8. PMID 41559596
Identifiers
NCT: NCT05740696 · XJTU1AF2023LSK-019